Debiopharm Honored As A 2020 Swiss Biotech Success Story Winner For Outstanding Achievements Over 40 Years

Supporting its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies, and financial resources. Debiopharm accepts this honor alongside other Swiss Biotech Success Story 2020 awardees including: Actelion, Helsinn, Venture Kick, >>Venture>>, Venturelab, and the noble prize-winner Professor Werner Arber. Supporting its members in a competitive market, the Swiss Biotech Association works to...

Supporting its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies, and financial resources. Debiopharm accepts this honor alongside other Swiss Biotech Success Story 2020 awardees including: Actelion, Helsinn, Venture Kick, >>Venture>>, Venturelab, and the noble prize-winner Professor Werner Arber.

"We are proud to be recognized by the Swiss Biotech association for this prestigious award. We know that through scientific research and fruitful collaborations, we can bring innovation to patients that will help them survive and thrive," expressed Bertrand Ducrey, CEO of Debiopharm, "Switzerland has all of the ingredients to form an important biotech hub that creates disruptive technologies for patients around the world." 

More About Debiopharm

Debiopharm develops, manufactures, and invests in innovative therapies and technologies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally. 

For more information, please visit www.debiopharm.com  

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews  

Debiopharm Contact 
Dawn Haughton 
Communication Manager 
[email protected] 
Tel: +41 (0)21 321 01 11